| http://www.w3.org/ns/prov#value | - THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases such as multiple sclerosis (MS) and diabetes, today announced that top-line data from the company???s Phase IIb study of Tovaxin?? will be presented at the World Congress on Treatment and Research in Mu
|
